Latest Rituximab Stories
SEATTLE, Dec. 6, 2010 /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc. ("the Company") (Nasdaq and MTA: CTIC) today announced new pixantrone end of study ("EOS") follow up results from the Company's pivotal phase III PIX301 trial, which results form the basis for the Company's recent Marketing Authorization Application (the "MAA") currently under review by the European Medicines Agency ("EMA"). The end-of-study results showed continued improvement in the trial's primary and secondary...
NEW YORK, Dec. 5, 2010 /PRNewswire/ -- See video from Roche Pharmaceuticals at: http://www.thenewsmarket.com/Releases/StoryDetailPage.aspx?GUID=8ccb0fab-c02c-45e7-96af-58336f5dcc25# Roche announced positive data from a Phase III study of Rituxan/MabThera (rituximab) in patients with advanced follicular lymphoma who did not have symptoms of disease (asymptomatic disease). Phase III study showed Rituxan/MabThera for initial use followed by continued use delayed need for additional therapy in...
ORLANDO, Fla., Dec. 5, 2010 /PRNewswire-USNewswire/ -- The next generation of drug therapies and enhanced treatment approaches for various forms of lymphoma are evolving as researchers continue to better understand how these cancers progress. Research will be presented today at the 52nd Annual Meeting of the American Society of Hematology introducing promising new options for the standard treatment of advanced asymptomatic follicular lymphoma, mantle cell lymphoma, and early, unfavorable...
NEW YORK, Nov. 29, 2010 /PRNewswire-FirstCall/ -- Pfizer (NYSE: PFE) said today that new data on investigational compounds in its hematology portfolio will be presented at the 52nd Annual Meeting of the American Society of Hematology (ASH) in Orlando, December 4-7. Key highlights include results from a Phase 3 study, called the BELA (Bosutinib Efficacy and safety in chronic myeloid LeukemiA) study, involving bosutinib for the treatment of newly diagnosed Philadelphia chromosome positive...
HORSHAM, Pa., Nov. 11, 2010 /PRNewswire/ -- Centocor Ortho Biotech Inc. has submitted a supplemental Biologics License Application (sBLA) to the U.S. Food and Drug Administration (FDA) seeking to expand the SIMPONI® physician label. The sBLA includes inhibition of the progression of structural damage and maintenance of improvement in signs and symptoms and physical function in the treatment of patients with active psoriatic arthritis (PsA). This submission represents the second sBLA...
THOUSAND OAKS, Calif., Nov. 11, 2010 /PRNewswire/ -- ImmunGene, Inc., a privately held drug development company focused on targeted antibody therapeutics with numerous anti-cancer functions built into a single therapy, announced today that a profile of the company and its pipeline is featured in the November 21 issue of BioWorld Today in the NewCo section http://www.bioworld.com/. The publication noted that, "ImmunGene is currently in advanced partnership discussion with several biotech and...
ATLANTA, Nov. 9, 2010 /PRNewswire/ -- The addition of Cimzia® (certolizumab pegol; CZP) to current therapy was associated with a rapid clinical response, improved function and reduced disease activity in a diverse group of adult rheumatoid arthritis (RA) patients reflecting those seen in daily clinical practice (including those with prior TNF-inhibitor use). These positive clinical trial data were presented during the American College of Rheumatology's (ACR) 2010 Annual Scientific...
ATLANTA, Nov. 8, 2010 /PRNewswire/ -- Magnetic resonance imaging (MRI) analyses from two Phase 3 clinical trials showed that once every four week subcutaneous injections of SIMPONI(®) (golimumab) 50 mg plus methotrexate resulted in statistically significant improvements in markers of inflammation and structural damage in patients with active rheumatoid arthritis (RA) compared with placebo plus methotrexate. Changes in disease activity were measured using the Rheumatoid Arthritis MRI...
ATLANTA, Nov. 5, 2010 /PRNewswire/ -- Cimzia® (certolizumab pegol) data demonstrating rapid and sustained improvements in managing moderate to severe rheumatoid arthritis (RA) symptoms, reducing disease activity and inhibiting joint damage progression will be exhibited during the American College of Rheumatology's 2010 Annual Scientific Meeting in Atlanta, November 7-11. Cimzia is indicated for the treatment of adult patients with moderately to severely active rheumatoid arthritis....
NEW YORK, Oct. 29 /PRNewswire/ -- See video from Roche Pharmaceuticals at: http://www.thenewsmarket.com/CustomLink/CustomLinks.aspx?GUID=23a45dd7-b318-43fa-8347-3c5321bad198&alertid=71250c6c-8d9b-4962-8576-f46b2ca2916d&bhcp=1 Roche announced on October 29 that the European Commission has approved the use of MabThera (rituximab) as a maintenance treatment for people suffering from follicular lymphoma who have responded to initial induction therapy. The approval of MabThera...
